CEL SCI CORP
SC 13E4/A, 1998-02-27
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: CEL SCI CORP, 424B3, 1998-02-27
Next: CHEMFAB CORP, S-8, 1998-02-27








                                      -1-

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                 SCHEDULE 13E-4

                          Issuer Tender Offer Statement
                Pursuant to Section l3(e)(l) of the Securities
                              Exchange Act of l934

                                (Amendment No. 2)


                                   CEL-SCI CORPORATION
                                (Name of Issuer)

                                   CEL-SCI CORPORATION
                      (Name of Person(s) Filing Statement)

                         Common Stock Purchase Warrants
                         (Title of Class of Securities)

                                         150-837-128
                      (CUSIP Number of Class of Securities)

                              William T. Hart, Esq.
                                  Hart & Trinen
                             l624 Washington Street
                             Denver, Colorado 80203
                                  303-839-006l
                 (Name, Address and Telephone Number of Person
               Authorized to Receive Notices and Communications
                 on Behalf of the Person(s) Filing Statement)

                               November 14, l997
                      (Date Tender Offer First Published,
                      Sent or Given to Security Holders)




                           Calculation of Filing Fee:

                (                     )                        )
                (   Transaction       )  Amount of Filing Fee  )
                (    Valuation*       )         $4,960         )
                (   $24,800,000       )                        )
                 ----------------------------------------------



<PAGE>


    The  valuation  set  forth  above is  based  upon  the  market  price of the
Warrants, assuming all Warrants are tendered pursuant to this offering.

    *Set forth the amount on which the filing fee is  calculated  and state how
it was determined.

    [X]  Check  box if any  part  of the  fee is  offset  as  provided  by  Rule
0-ll(a)(2)  and identify the filing with which the offsetting fee was previously
paid.  Identify the previous filing by registration  statement number,  or the
Form or Schedule and the date of its filing.

    Amounts Previously Paid:  $8,567
    Form or Registration Nos.:   333-31489
    Filing Party:    CEL-SCI Corporation
    Dates Filed:    August 4, l997

Item l.  Security and Issuer

              (a) The name of the issuer is CEL-SCI Corporation.  The address of
its principal executive office is 66 Canal Center Plaza, Suite 510, Alexandria,
Virginia  22314.

              (b) This  offer  relates to the  issuer's  Common  Stock  Purchase
Warrants (the "Warrants"),  of which 5,175,000  Warrants are outstanding as of
the date hereof.  A Warrant  holder who tenders five  Warrants and $6.00 in cash
will receive one share of the issuer's common stock (the "Common Stock") and one
Series  A  Warrant.  Warrants  may  be  acquired  from  officers,  directors  or
affiliates of the issuer.

              (c)  Incorporated  by  reference  to that  portion of the issuer's
Registration  Statement on Form S-3, SEC File No.  333-31489 (the  "Registration
Statement") captioned "Market for the Company's Common Stock."

              (d) Not applicable.

Item 2.  Source and Amount of Funds or Other Consideration.

         (a)  See Item l(b) above.
         (b)  Not applicable.

Item     3. Purposes of the Tender Offer and Plans or Proposals of the Issuer or
         Affiliate.

         Incorporated  by  reference  to  those  portions  of  the  Registration
Statement captioned "Plan of Distribution - Exchange Offer."

Item 4.  Interest in Securities of the Issuer.

         None.



<PAGE>


Item 5.  Contracts, Arrangements, Understandings or Relationships with Respect
to the Issuer's Securities.

         None.

Item 6.  Persons Retained, Employed or to be Compensated.

         None.

Item 7.  Financial Information.

              (a)   Incorporated   by  reference   to  those   portions  of  the
Registration Statement captioned "Prospectus Summary".

              (b) Not applicable.

Item 8.  Additional Information.

         Between  January  9, 1998 and  February  17,  1998 the  holders  of the
Company's  outstanding Warrants were given the opportunity to purchase one share
of the Company's  Common Stock and one Series A Warrant for $6.00 (the "Exchange
Offer").  The Series A Warrant,  allows the holder to  purchase  one  additional
share of the Company's  Common Stock for $10.00 at any time prior to February 7,
2000.

         During  the  period  of  the  Exchange  Offer,  582,025  warrants  were
tendered, the Company received proceeds of approximately $698,000 and a total of
116,405 Series A Warrants were issued to the warrant  holders  participating  in
the Exchange Offer.

Item 9.  Material to be Filed as Exhibits.

              (a)  Letter of Transmittal.  See also (e) below.

              (b)  None.

              (c)  None.

              (d)  None.

              (e) Prospectus  filed as part of a Registration  Statement on Form
S-3, Registration Number 333-31489. (Previously filed)

                   Prospectus supplement dated January 27, 1998

              (f)  None.



<PAGE>



                                    Signature

         After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.

                                       CEL-SCI CORPORATION

February 27, 1998                 By: /s/ Geert R. Kersten
                                      --------------------
                                            Geert R. Kersten
                                            Chief Executive Officer








© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission